Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...
The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.
Hosted on MSN2mon
LLY's Zepbound Outshines NVO's Wegovy in Head-to-Head Obesity StudyIn the phase IIIb 72-week study, Zepbound led to an average weight loss of 20.2% of body weight in adults with obesity or overweight, compared to 13.7% for Wegovy, which represents a 47% greater ...
Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Patients on the weight-loss drug Zepbound regained weight almost one year ...
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli LIlly’s Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback